Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Februar 2018 07:50 ET | Quelle: Arch Therapeutics, Inc.

Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application

FRAMINGHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Positive data from a clinical study of patients undergoing dermatologic surgery and treated with the AC5™ was published in the peer-reviewed...
02. Januar 2018 07:50 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January 8th, 2018

FRAMINGHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
18. Dezember 2017 07:50 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA

FRAMINGHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
28. November 2017 07:50 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017

FRAMINGHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
20. September 2017 07:55 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences

FRAMINGHAM, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic...
12. September 2017 07:55 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity

FRAMINGHAM, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices...
06. September 2017 07:55 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

FRAMINGHAM, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
25. Juli 2017 07:55 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel

FRAMINGHAM, MA--(Marketwired - Jul 25, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
06. Juni 2017 12:25 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

FRAMINGHAM, MA--(Marketwired - Jun 6, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
22. Mai 2017 07:57 ET | Quelle: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

FRAMINGHAM, MA--(Marketwired - May 22, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be...

Vorherige Seite